BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
Key Highlights
- ➤28 acoramidis abstracts, including 12 new posters, will be presented at ISA 2026
- ➤Acoramidis data cover kidney function, heart-failure outcomes, and treatment patterns
- ➤Bayer will present German real-world data comparing acoramidis with tafamidis
- ➤Acoramidis is approved in the U.S., Singapore, Europe, Japan, Switzerland, UK, Brazil, and Australia
- ➤Acoramidis is indicated to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM
Expert Statements
Prem Soman, M.D., University of Pittsburgh Medical Center
“Safety and Efficacy of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and CKD Stage 4: Insights from the ATTRibute-CM Trial”
Daniel P. Judge, M.D., Medical University of South Carolina
“eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) With and Without Atrial Fibrillation: Findings from the ATTRibute-CM Trial”
Kevin M. Alexander, M.D., Stanford University School of Medicine
“eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients with Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings from the ATTRibute-CM Trial”
Margot K. Davis, M.D., Division of Cardiology, University of British Columbia
“eGFR Dip After Acoramidis Initiation and Acoramidis-Associated Clinical Benefits in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) With and Without Diabetes: Findings from the ATTRibute-CM Trial”
Julian D. Gillmore, M.D., Ph.D., University College London, Royal Free London Hospital
“Early eGFR Dip Following Acoramidis Initiation in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Is Not Accompanied by Clinically Meaningful Changes in Laboratory Measures or Blood Pressure: An ATTRibute-CM Analysis”
Richard F. Wright, M.D., Pacific Heart Institute
“Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy: Real-World Evidence of Lower Transthyretin Silencer Therapy Initiation With Acoramidis”
Liana Hennum, M.P.T., M.H.A., BridgeBio
“Treatment Patterns in Newly Diagnosed Patients with Transthyretin Amyloid Cardiomyopathy in the United States: Results from a Real-World Study Show Transthyretin Stabilizers Are the Predominant First-Line Treatment”
Thibaud Damy, M.D., Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Sud
“Early Reduction of Heart Failure Events with Acoramidis: A Time-to-Benefit Analysis of ATTRibute-CM”
Kevin M. Alexander, M.D., Stanford University School of Medicine
“An Indirect Comparison of the Efficacy of Acoramidis and Tafamidis on Cardiovascular Outcomes and Mortality in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Results from an Anchored Matching-Adjusted Analysis of ATTRibute-CM and ATTR-ACT”
Daniel P. Judge, M.D., Medical University of South Carolina
“eGFR Dip Thresholds and Clinical Outcomes with Acoramidis: A Sensitivity Analysis from ATTRibute-CM”
Sandesh Dev, M.D., Southern Arizona Veterans Affairs Health Care System
“Treatment Patterns and Clinical Phenotypes in a National VA ATTR-CM Cohort Across Diagnostic and Therapeutic Eras”
Richard F. Wright, M.D., Pacific Heart Institute
“Acoramidis Reduces Days Lost to Death and/or Cardiovascular-Related Hospitalization, Preserving Time Alive Outside the Hospital in Patients With Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM”
Frederick L. Ruberg, M.D., Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center
“Long-Term Effects of Acoramidis on Mortality in Variant Transthyretin Amyloid Cardiomyopathy, Including p.Val142Ile: Findings From the Open-Label Extension of ATTRibute-CM”
Daniel P. Judge, M.D., Medical University of South Carolina
“eGFR Dips After Acoramidis Initiation Are Associated With Clinical Benefits in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From the ATTRibute-CM Trial”
Daniel P. Judge, M.D., Medical University of South Carolina
“Protective Effect of Acoramidis on Kidney Function in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings From ATTRibute-CM and its Open-Label Extension Study”
Hanna K. Gaggin, M.D., Massachusetts General Hospital
“Serum Transthyretin to NT-proBNP Ratio as a Novel Prognostic Measure in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial”
John Isaiah Jimenez, Stanford University School of Medicine
“A Validated Transthyretin Amyloid Cardiomyopathy (ATTR-CM) United States (US) Claims-Based Coding Algorithm (ValidATTR-US)”
Shana Littleton, PhD, Center for Individualized and Genomic Medicine Research
“Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform”
Liana Hennum, M.P.T., M.H.A., BridgeBio
“Falls and Fractures Drive Increased Hospitalizations and Costs in Patients with Transthyretin Amyloid Cardiomyopathy Compared with Controls”
Onyedika J. Ilonze, M.D., Indiana University School of Medicine
“NT-proBNP and Serum Transthyretin and Their Relationship with Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM”
Prem Soman, M.D., University of Pittsburgh Medical Center
“Effect of Acoramidis on the Temporal Variability of Serum Transthyretin and its Influence on Outcomes: Insights from the ATTRibute-CM Trial”
Awais Sheikh, MBChB, National Amyloidosis Centre, University College London, Royal Free London Hospital
“Long-Term Improvement in Myocardial Structure and Function in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treated with Acoramidis Compared with a Natural History Cohort”
Prem Soman, M.D., University of Pittsburgh Medical Center
“Recovery of NT-proBNP Concentrations and Heart Failure-Related Health Status After Cardiovascular-Related Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from ATTRibute-CM”
Richard F. Wright, M.D., Pacific Heart Institute
“Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy: Early Real-World Evidence Favors Acoramidis”
Liana Hennum, M.P.T., M.H.A., BridgeBio
“Budget Impact of Adding Acoramidis to Formulary for the Treatment of Transthyretin Amyloid Cardiomyopathy: A United States Health Plan Analysis”
Kevin M. Alexander, M.D., Stanford University School of Medicine
“Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Findings from ATTRibute-CM Using Multistate Modeling”
Margot K. Davis, M.D., Division of Cardiology, University of British Columbia
“Acoramidis Reduces Risk of Cardiovascular-Related Mortality and Hospitalization in Female Patients with Transthyretin Amyloid Cardiomyopathy”
Roman Pfister, M.D., University Hospital Cologne
“Oral Diuretic Intensification in Real-World ATTR-CM Patients on TTR Stabilizing Therapy: The mODIficATTR Study”
PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced 28 abstracts on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) comprised of 12 new posters, seven encore poster presentations, and nine encore posters, will be shared at the XX International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18, 2026, in Montevideo, Uruguay. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Bayer, BridgeBio's exclusive European licensing partner of acoramidis, will share five new presentations, including new real-world data from Germany comparing acoramidis with tafamidis on oral diuretic intensification, a marker of outpatient worsening heart failure.
Get started
Create a free account to read the full story.